You have 10 free articles left this month. Get your freeBasic subscription now and gain instant access to more.

Serbia's Ako Med to distribute Unyvero diagnostic platform of Curetis in SEE

Author Radomir Ralev
Serbia's Ako Med to distribute Unyvero diagnostic platform of Curetis in SEE Author: Darko Stojanovic; License: CC0 Creative Commons

BELGRADE (Serbia), July 30 (SeeNews) - Serbian medical devices distributor Ako Med has become distributor of the Unyvero diagnostic platform of German molecular microbiology diagnostics solutions developer Curetis in several countries in Southeast Europe, Curetis said on Tuesday.

Curetis has signed two distribution agreements with the Bosnian and Serbian branches of Ako Med, under which the company has the exclusive right to commercialise the Unyvero A50 instrument system and application cartridges for the diagnosis of severe infections in hospitalised patients in Serbia, North Macedonia, Bosnia and Herzegovina, and Montenegro, Curetis said in a statement.

The agreements have a term of initially three years and can be extended by two-year increments. In return, Ako Med has committed to significant minimum purchases of Unyvero instruments and application cartridges over the initial three-year term of the agreement.

"Working with Curetis is a great opportunity for us as we believe that patients will greatly benefit from the rapid diagnosis of life-threatening infections with the Unyvero platform," said Jovan Radakovic, director of Ako Med Serbia. "We believe that our markets are very open to innovations in molecular microbiology and we are already actively working on including Unyvero in several tender offers."

The process for the registration of the products in the respective countries has been initiated and is expected to be completed in the next couple of months, Curetis said.

Unyvero is a versatile, fast and highly automated molecular diagnostic platform for the detection of pathogens and antimicrobial resistance markers in a range of severe infectious disease indications. Results are available within hours, thereby facilitating improved patient outcomes, stringent antibiotic stewardship and health-economic benefits.